1. T2DM and CV Outcomes Trials: A Deep Dive!

2. Completed DPP-4 Inhibitor CV Outcomes Trials in T2DM

3. SAVOR-TIMI 53: Study Design

4. December 2008 FDA Guidance on Evaluating CV Risk in New Antidiabetic Therapies for T2DM

5. SAVOR-TIMI 53: Primary Endpoint

6. SAVOR-TIMI 53: Hospitalization for HF

7. EXAMINE: Study Design

8. EXAMINE: Primary Endpoint

9. EXAMINE: Hospitalization for HF

10. TECOS: Study Design

11. TECOS: Effect of Sitagliptin vs Placebo on CV Outcomes in T2DM

12. TECOS: Hospitalization for HF

13. Future DPP-4 CV Outcomes Trials in T2DM

14. ELIXA: Study Design

19. EMPA-REG OUTCOME: Study Design

20. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

21. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

22. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on Individual CV Endpoints

23. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on All-cause Mortality

24. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on HF Hospitalization

25. EMPA-REG OUTCOME: CV Death in Subgroups of Patients

26. EMPA-REG OUTCOME: HF Hospitalization in Patients With vs Without HF at Baseline

27. Ongoing SGLT2 Inhibitor CV Outcomes Trials

28. ADA/EASD Position Statement: Antihyperglycemic Therapy in T2DM

29. Abbreviations

30. Abbreviations (cont)

31. Abbreviations (cont)

32. Abbreviations (cont)